NeoGenomics, Inc. (NEO) Stock
NEO Key Statistics
About NeoGenomics, Inc.
NeoGenomics, Inc. specializes in providing cancer-focused diagnostic and testing services through an extensive network of laboratories located across the United States, Europe, and Asia. The company operates through two distinct divisions: Clinical Services and Pharma Services. Its comprehensive offerings cater to a diverse clientele, including hospitals, reference laboratories, pathologists, oncologists, clinicians, pharmaceutical companies, and researchers. NeoGenomics' advanced testing capabilities encompass cytogenetics, which examines normal and abnormal chromosomes in relation to disease; fluorescence in-situ hybridization (FISH) for detecting and pinpointing specific DNA sequences and genes on chromosomes; and flow cytometry, used to measure cell population characteristics. Additionally, the company provides immunohistochemistry and digital imaging services, enabling the localization of cellular proteins in tissue sections, visualization of scanned slides, and quantitative analysis. Molecular testing, focusing on DNA/RNA analysis and gene structure/function, is also a key offering, alongside morphologic analysis where pathologists microscopically diagnose cells. Beyond clinical diagnostics, NeoGenomics supports pharmaceutical clients' oncology programs from discovery to commercialization and acts as a reference laboratory for anatomic pathology testing. The company, founded in 2001 and headquartered in Fort Myers, Florida, also maintains a strategic alliance and laboratory services agreement with Inivata Limited.
CEO: Anthony Zook. Company website
NEO — Frequently Asked Questions
What is the NEO stock price today?
NeoGenomics, Inc. (NEO) trades at $16.83, down 0.77% on the day, as of Nov 12, 2026 09:20 UTC.
What is NeoGenomics, Inc.'s market cap?
NeoGenomics, Inc. has a market capitalisation of $2.18B, calculated from the live NEO share price and shares outstanding.
What is the P/E ratio of NEO?
NEO has no meaningful price-to-earnings ratio: NeoGenomics, Inc. lost $0.25 per share over the last twelve months, and a P/E is only defined on positive earnings.
How much revenue does NeoGenomics, Inc. make?
NeoGenomics, Inc. generated revenue of $787.75M over the trailing twelve months, which puts the stock at 2.76 times sales.
What is the 52-week range for NEO?
NEO has traded between $7.07 and $20.15 over the past 52 weeks, and the last price is 16.5% below that high.
Is NeoGenomics, Inc. profitable?
No. NeoGenomics, Inc. is loss-making, with a net margin of -4.10% over the trailing twelve months.
What is the analyst price target for NEO?
Wall Street analysts rate NEO Buy, with an average price target of $22.50, 33.7% above the current price.
What sector is NeoGenomics, Inc. in?
NeoGenomics, Inc. is classified under the Healthcare sector and the Medical - Diagnostics & Research industry, and is domiciled in US.
Who is the CEO of NeoGenomics, Inc.?
Anthony Zook is the chief executive of NeoGenomics, Inc., which employs 2,500 people.
Where can I track NEO in real time?
QFI Terminal shows NEO with live charts, full financials, the options chain with gamma exposure, institutional ownership and analyst ratings on one screen. The free plan has no time limit and asks for no card.
See NEO live in QFI Terminal
Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.
Open NEO in Terminal See plans